Cancer Management and Research (Sep 2022)
Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma
Abstract
Xiaohong Liu,1 Dedong Cao,1 Hui Liu,2 Dong Ke,3 Xiaokang Ke,4 Ximing Xu1 1Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China; 2Department of Hematology, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China; 3Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of China; 4Department of Pathology; Renmin Hospital of Wuhan University, Wuhan, 430060, People’s Republic of ChinaCorrespondence: Ximing Xu, Department of Oncology, Renmin Hospital of Wuhan University, 99 Ziyang Road, Wuhan, 430060, People’s Republic of China, Tel +8627-88041911, Email [email protected]: This study aimed to analyze the clinical features and survival of primary small intestinal diffuse large B-cell lymphoma (PsI-DLBCL), and establish and independently validate a prognostic nomogram for individual risk prediction.Patients and methods: Data for 24 patients from the Renmin Hospital of Wuhan University were used as an independent validation cohort, data for 1144 patients with PsI-DLBCL from the SEER database were randomly assigned to training (N=817) and internal validation (N=327) sets. The survival nomogram was constructed with the most significant factors associated with OS using Univariate and multivariate analyses on the training set. Decision curve analysis (DCA) was conducted. Internal validation was SEER validation set. Our cancer center cohort was used as an external validation set to further verify the survival nomogram.Results: Five clinicopathological feature factors associated with OS of the training set yielded (age, marital status, Ann Arbor stage, surgery for primary site and chemotherapy), which were used to create a survival nomogram. Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values. The stability of our survival nomogram was explained by internal and external validation data.Conclusion: Our nomogram proposes the clinical and therapeutic factors affecting OS for patients with PsI-DLBCL. It shows that chemotherapy and surgery are beneficial to patients in the choice of treatment options. These results suggest that a survival nomogram may be better at predicting OS for PsI-DLBCL patients.Keywords: large B-cell lymphoma, non-Hodgkin, small intestine, SEER, nomogram
